Published in Nature · View the paper (DOI)
Researchers have identified mutations defining two common subtypes of MPAL, B/myeloid and T/myeloid, and shown that some patients may benefit from targeted therapies. The study provides a genetically based framework for designing clinical trials to develop more effective treatments.
Coverage from 2 institutions